Skip to main content

Antonio Digiandomenico

Nov 10, 2026

13:18
And I guess thinking about monoclonal antibody therapeutics, what's sort of the, I guess, the next step or like how, like obviously you're trying to make them better, make them more efficacious, you know, what are sort of the, some of the big questions of these particular types of therapeutics?
13:38
So I think one of the biggest things for monoclonal antibodies is When you're thinking about the patient experience, you want that coverage to be as long-term as possible.
13:51
And as you may know, antibodies, typically we usually develop human IgG1s as monoclonal antibodies because they have a lot of favorable characteristics in terms of half-life and so forth.
14:06
That half-life for normal IgG is usually about 21 days.
14:11
And so the question that we always have is, well, how can we make this half-life longer so that you don't have to continually treat with this particular drug? And so you look at antibody half-life extension technology.
14:24
I know we have a couple here at AstraZeneca and many other companies used to extend the half-life technology.
14:31
We've seen with some of our other drugs that we can provide upwards of 90 to 100 days of half-life coverage.
17:52
And then I guess thinking about your field in general, so like developing these monoclonals, what are some of the challenges that your field faces right now? And I guess maybe talking a little bit about also, you know, what has AI or the ability to use AI, has that actually been beneficial for your program? Are you using it a lot? Things like that.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.